If approved, this off-the-shelf, fixed-duration Columvi combination will be the first bispecific antibody regimen available for patients with DLBCL following relapse ...

The era of job security without A.I. proficiency is over. A new study reveals that employers now prioritize A.I. skills over ...

Quatrro Business Support Services (Quatrro), a leading provider of cost-effective, tech-enabled outsourced finance and accounting, human resources, application development, and IT support services to ...

Oxford Nanopore Technologies plc ( OTCPK:ONTTF) Q4 2024 Results Conference Call March 4, 2025 4:30 AM ET Gordon Sanghera - Chief Executive Officer Nick Keher - Chief Financial Officer ...

A blood test being ... health systems money. Roche and Lilly are also working on another Elecsys test that measures pTau181 protein assay and apolipoprotein (APOE) E4 assay in human blood plasma ...

Operator Good afternoon, and welcome to the Sarepta Therapeutics fourth quarter and full year 2024 financial results conference call. As a reminder, today's program is being recorded. At this time, ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

Q4 2024 Earnings Call Transcript February 26, 2025 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.5, expectations were $1.38. Operator: Good afternoon. And welcome to the ...

The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...